Bassil Dahiyat, Xencor CEO

J&J signs on Xen­cor for a $100M li­cens­ing deal tar­get­ing CD20, look­ing to press its ad­van­tage in bis­pecifics

With a re­cent ap­proval for lung can­cer bis­pe­cif­ic ami­van­tam­ab, J&J is look­ing to build a fran­chise in that space with a grow­ing crop of drugs in the pipeline. The drug gi­ant has now tapped a fa­mil­iar part­ner to dri­ve that work ahead, and the pair is go­ing af­ter a well-known tar­get.

J&J’s Janssen unit has inked a li­cens­ing deal worth $100 mil­lion in up­front cash and $25 mil­lion in eq­ui­ty for glob­al li­cens­ing rights to Xen­cor’s CD20/CD3 bis­pe­cif­ic an­ti­body plam­o­tam­ab cur­rent­ly in Phase I test­ing against B cell ma­lig­nan­cies, the com­pa­nies said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.